Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hazard Ratio01:12

Hazard Ratio

116
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
116
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

163
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
163

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Machine learning-based prediction of mortality and hospitalization in diabetic patients with heart failure with preserved ejection fraction: the GUARDIAN-P risk score.

European heart journal. Digital health·2026
Same author

The Impact of GLP-1-Based Therapies on Cardiovascular Outcomes in Type 2 Diabetes: A Comprehensive Systematic Review and Network Meta-Analysis.

Diabetes, obesity & metabolism·2026
Same author

Cardiovascular-kidney-metabolic interplay in patients with atrial fibrillation receiving direct oral anticoagulants.

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology·2026
Same author

Diagnosis of Cardiac Amyloidosis on Echocardiography Using Artificial Intelligence.

Circulation. Cardiovascular imaging·2026
Same author

Artificial Intelligence-Enabled Echocardiographic Assessment of Right Ventricular Function.

medRxiv : the preprint server for health sciences·2026
Same author

LV Diastolic Dysfunction and Inappropriate LV Filling Pressure Escalation: The Core of Exercise Intolerance in Heart Failure.

Korean circulation journal·2025
Same journal

Stable, Progressive, and Acute Valve Syndrome in Severe Aortic Stenosis: Insights from the CURRENT AS Registry-2.

Journal of the American Heart Association·2026
Same journal

<i>LPA</i> Kringle IV Type-2 Genetic Variants Are Associated With Apolipoprotein (a) Size, Hypertension, and Nonfasting Glucose Levels.

Journal of the American Heart Association·2026
Same journal

Hemorrhagic Transformation Mediates Stress Hyperglycemia Effect on Functional Outcome in Minor Ischemic Stroke.

Journal of the American Heart Association·2026
Same journal

Mental Disorders After Cardiac Implantable Electronic Device Implantation in Young Individuals.

Journal of the American Heart Association·2026
Same journal

Hypertensive Disorders of Pregnancy Associated With Cerebral Small Vessel Disease Decades Later.

Journal of the American Heart Association·2026
Same journal

Neighborhood-Level Racial and Ethnic Residential Segregation and Incidence of Atrial Fibrillation: The Multi-Ethnic Study of Atherosclerosis.

Journal of the American Heart Association·2026
See all related articles

Related Experiment Video

Updated: Jun 28, 2025

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
00:04

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

10.7K

ELUCIDATE Trial: A Single-Center Randomized Controlled Study.

Jiun-Lu Lin1,2, Sung-Chen Liu1,2, Tze-Fan Liu2

  • 1Division of Endocrinology and Metabolism, Department of Internal Medicine MacKay Memorial Hospital Taipei Taiwan.

Journal of the American Heart Association
|April 19, 2024
PubMed
Summary
This summary is machine-generated.

Early dapagliflozin treatment in type 2 diabetes patients improved cardiac remodeling and function. This sodium-glucose cotransporter 2 inhibitor shows promise for preventing diabetic cardiomyopathy.

Keywords:
clinical trialdapagliflozinechocardiographysodium–glucose cotransporter 2 inhibitorstype 2 diabetesventricular remodeling

More Related Videos

E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy
06:28

E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy

Published on: August 1, 2019

8.3K
Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
08:36

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment

Published on: April 19, 2024

505

Related Experiment Videos

Last Updated: Jun 28, 2025

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
00:04

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

10.7K
E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy
06:28

E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy

Published on: August 1, 2019

8.3K
Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
08:36

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment

Published on: April 19, 2024

505

Area of Science:

  • Cardiology
  • Endocrinology
  • Pharmacology

Background:

  • Type 2 diabetes (T2D) is associated with increased risk of cardiovascular complications.
  • Sodium-glucose cotransporter 2 (SGLT2) inhibitors, like dapagliflozin, are established treatments for T2D and have shown cardiorenal benefits.
  • The impact of early dapagliflozin intervention on left ventricular (LV) remodeling in T2D patients without pre-existing cardiovascular disease (CVD) is not well understood.

Purpose of the Study:

  • To investigate the effect of early dapagliflozin add-on therapy on LV remodeling and cardiac function in patients with asymptomatic type 2 diabetes.
  • To evaluate changes in LV dimensions, mass, and strain parameters following dapagliflozin treatment.
  • To assess the potential of dapagliflozin in the primary prevention of diabetic cardiomyopathy.

Main Methods:

  • The ELUCIDATE trial was a prospective, open-label, randomized study involving 76 patients with asymptomatic T2D and preserved LV ejection fraction (≥50%).
  • Patients were randomized to receive dapagliflozin 10 mg/day add-on therapy or standard of care.
  • Speckle-tracking echocardiography was used to measure cardiac global longitudinal strain at baseline and 24 weeks.

Main Results:

  • Dapagliflozin treatment resulted in significant reductions in LV dimension, LV end-systolic volume, and LV mass index compared to standard care.
  • Patients on dapagliflozin showed a significant increase in LV global longitudinal strain and improved systolic and early diastolic strain rates.
  • No significant changes were observed in insulin resistance, NT-proBNP levels, or other biomarkers at 6 months.

Conclusions:

  • Early dapagliflozin add-on therapy promotes favorable cardiac remodeling and enhances cardiac mechanical function in asymptomatic type 2 diabetes patients.
  • These findings support the use of dapagliflozin for the primary prevention of diabetic cardiomyopathy.
  • Dapagliflozin may offer a protective effect on the heart in T2D patients even before the onset of overt cardiovascular disease.